11:49 AM EST, 01/30/2025 (MT Newswires) -- Bausch Health's ( BHC ) Q4 results on Feb. 19 will be mainly eyed by investors for the company's 2025 guidance, a potential full separation of Bausch + Lomb ( BLCO ) , and upcoming debt maturities in Q4 this year, RBC Capital Markets said Thursday.

RBC said it expects Bausch Health ( BHC ) to post Q4 revenue of $2.56 billion, above the FactSet consensus of $2.52 billion, and adjusted EBITDA of $918.8 million, below the FactSet consensus of $939 million.

For 2025, RBC expects Bausch Health ( BHC ) to deliver revenue of $10.01 billion, above consensus at $9.9 billion, and adjusted EBITDA of $3.42 billion, in line with consensus forecasts.

Meanwhile, the investment firm said it trimmed Bausch Health's ( BHC ) price target to $10 from $11 as it's decreasing the Bausch + Lomb ( BLCO ) sale scenario weighting to 60% from 75% after a media report saying that Blackstone (BX) will likely drop out of a consortium with TPG (TPG) to take out the eye care company.

A potential sale of Bausch + Lomb ( BLCO ) would result in about $6.5 billion to $7.7 billion in proceeds to Bausch Health ( BHC ), RBC said.

The investment firm has a sector perform rating on Bausch Health ( BHC ).

Price: 7.46, Change: -0.01, Percent Change: -0.19